PACE trial: What Menarini’s biomarker data reveals about escalating treatment in metastatic breast cancer

PACE trial: What Menarini’s biomarker data reveals about escalating treatment in metastatic breast cancer

Menarini Silicon Biosystems has reported new secondary analysis results from the PACE trial, reinforcing the potential of its CELLSEARCH Circulating Tumor Cell (CTC) enumeration system as a predictive biomarker for guiding treatment escalation in hormone receptor-positive, HER2-negative metastatic breast cancer. Published in Clinical Cancer Research, the findings suggest that CTC counts in blood samples could […]

Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?

Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?

Kazia Therapeutics Limited has presented new clinical and translational data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its investigational brain-penetrant PI3K/mTOR inhibitor, may suppress circulating tumor cell clusters and reverse immune exhaustion in two of the most treatment-resistant breast cancer subtypes—HER2-positive metastatic breast cancer and triple-negative breast cancer. The early evidence, […]